Press release
Fabry Disease Market Size in the 7MM is Estimated to Exceed USD 3,898.0 Million by 2035
Fabry Disease Market Size in the 7MM is Estimated to Exceed USD 3,898.0 Million by 2035
The 7 major fabry disease markets reached a value of USD 1,637.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3,898.0 Million by 2035, exhibiting a growth rate (CAGR) of 8.20% during 2025-2035.
The Fabry disease market is growing rapidly because of treatment options and the awareness and diagnostic methods being developed.
What is Fabry disease?
Fabry disease is a rare genetic disorder caused by the deficiency of the enzyme alpha-galactosidase A, which accumulates harmful substances in the cells of the body, affecting different organs.
The expansion of the market is mainly attributable to the growing adoption of enzyme replacement therapies (ERTs). ERTs, including agalsidase beta and pegunigalsidase alfa, have formed the backbone for treating Fabry disease by decreasing the cellular accumulation of globotriaosylceramide (Gb3). Newly approved ERTs with greater efficacy and shorter infusion times have improved compliance and outcomes for those patients.
Request for a sample of this report: https://www.imarcgroup.com/fabry-disease-market-report/requestsample
With the rise of oral chaperone therapies, patients with amenable mutations might have a more comfortable treatment option, as these stabilize the defective enzyme, improving its activity while reducing substrate accumulation. An increasing pipeline for such treatments reflects well for the market's future.
Similarly, the advent of diagnostic techniques and technologies has strengthened the market growth. The European Union has taken the bold step of mandating several newborn screening programs, whereas genetic testing is available since early diagnosis through these approaches is an intervention point especially useful in preventing irreversible organ damages with progressive Fabry disease.
Regarding geography, North America holds sway over the Fabry disease market because of advanced healthcare facilities, high awareness levels, goodwill reimbursement policies, etc. However, the fast-growing areas in Fabry disease treatment markets are to be Asia-Pacific regions, by virtue of a rise in healthcare expenditure, rising awareness for Fabry disease, and expansion of gene diagnostic centers.
The market growth is also supported by the continuous research and development activities. Several companies are working toward gene therapies that will offer a chance for a one-time treatment to reverse the genetic defect. Any changes arising from such inventions will lay a new foundation in the treatment of Fabry disease.
Ask the Analyst for Customization and Get Full Insights with TOC: https://www.imarcgroup.com/request?type=report&id=30204&flag=E
The report also provides a detailed analysis of the current fabry disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Competitive Landscape With Key Players:
The competitive landscape of the fabry disease market has been studied in the report with the detailed profiles of the key players operating in the market.
Sanofi
Chiesi/Protalix Biotherapeutics
Amicus Therapeutics
uniQure
AceLink Therapeutics
IMARC Group Offers Other Reports:
Autism Spectrum Disorder Market https://www.imarcgroup.com/autism-spectrum-disorder-market
Amblyopia Market https://www.imarcgroup.com/amblyopia-market
Gastroesophageal Reflux Disease Market https://www.imarcgroup.com/gastroesophageal-reflux-disease-market
Surgical Site Infections Market https://www.imarcgroup.com/surgical-site-infections-market
Adeno-associated Virus Gene Therapy Market https://www.imarcgroup.com/adeno-associated-virus-gene-therapy-market
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
About Us:
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Market Size in the 7MM is Estimated to Exceed USD 3,898.0 Million by 2035 here
News-ID: 4055970 • Views: …
More Releases from IMARC Group
Brewery Consulting Business Setup Guide: Revenue Model, Cost Analysis & Market I …
Overview:
IMARC Group's "Brewery Consulting Business Plan and Project Report 2025" provides a detailed and data-driven roadmap for establishing and operating a successful brewery consulting business. The report highlights industry performance, key market trends, operational models, investment needs, and profitability forecasts. It serves as a valuable resource for entrepreneurs, investors, consultants, and business strategists. It also offers comprehensive guidance on Brewery Consulting Business setup, covering infrastructure planning, service offerings, resource allocation,…
Xenon Prices, Latest Trend, Demand, Index & Uses 2025
North America Xenon Prices Movement Q2:
Xenon Prices in USA:
During the second quarter of 2025, Xenon Prices in the USA reached 2,966 USD/MT in June. Prices remained elevated due to restricted output from air separation units and steady demand from the semiconductor and medical imaging industries. Heavy reliance on imports added cost pressures, with logistics and procurement challenges further influencing final market prices. The supply environment stayed tight, with minimal fresh…
Philippines Potato Chips Market Size Worth USD 233.12 Million From 2025 to 2033
Market Overview
The Philippines potato chips market reached a market size of USD 158.40 Million in 2024. It is expected to grow to USD 233.12 Million by 2033, driven by factors such as rising premium snack demand, international brand presence, and expanding retail and e-commerce networks. These trends are improving product innovation and accessibility, broadening consumer options and frequency of purchase. The forecast period for this market is 2025-2033, with a…
Philippines Banking Market 2026 | Projected to Reach USD 62.6 Billion by 2034 | …
Market Overview
The Philippines banking market reached a size of USD 10.4 Billion in 2025 and is projected to expand to USD 62.6 Billion by 2034, exhibiting a growth of 22.07% CAGR. This growth is supported by rising financial inclusion, a growing middle class, and strong remittance inflows that boost household finances. Innovations in digital banking and fintech, supported by government policies promoting financial inclusion and cashless transactions, are transforming the…
More Releases for Fabry
Key Factor Supporting Global Fabry Disease Treatment Market Development in 2025: …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Fabry Disease Treatment Market Size By 2025?
The valuation of the Fabry disease treatment market has experienced robust expansion recently, projected to advance from $2.09 billion in 2024 up to $2.27 billion by 2025, reflecting an 8.8% compound annual growth rate during this timeframe. This…
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
